World’s First: Bacon Without Pigs is Finally Here

Various packaged pork products displayed in a grocery store — Photo: haireena / Shutterstock

The arrival of bacon grown from pig cells rather than whole animals marks a quiet but profound shift: for the first time, one of the world’s most popular meats can be made without pigs, slaughterhouses, or farms, yet still behave like pork on the plate.

Key Points

UK startup Higher Steaks (now Uncommon) developed a prototype bacon made mostly from cultivated pig cells, blended with plant ingredients.
The bacon is a hybrid: roughly 70% cultivated muscle cells and 30% plant-based fats and proteins, created without bovine serum.
The product is not yet authorised or sold; in the UK it would need to pass “novel food” safety and regulatory assessment before market entry.
Cultivated bacon sits in a broader pattern where bold sustainability and welfare claims arrive years before large-scale proof or farm-level impact.

From Pig Cells to Bacon: What “Bacon Without Pigs” Actually Means

When people hear “bacon without pigs,” they often imagine a purely synthetic product or a flavouring trick. Higher Steaks’ work is more literal: it starts with real pig cells and ends with a strip that looks and cooks like bacon, but those cells never belonged to a living, sentient animal on a farm. The company’s prototype rashers are what the field calls cultivated meat—muscle and fat tissue grown outside the animal, in controlled bioreactors, then structured into familiar cuts. In this case, the cut is bacon, a product defined as much by its fat streaks and sizzle as by its origin.

To get there, Higher Steaks uses induced pluripotent stem cells (iPSCs), an adaptable cell type that can be coaxed into becoming muscle or fat. A small, minimally invasive sample of cells is taken from a pig, then reprogrammed into iPSCs and expanded in a nutrient-rich growth medium. Over several weeks, those cells proliferate into large quantities of tissue. Plant-derived proteins, fats, and starches are added as binders and texture components, producing a hybrid strip made of roughly 70% cultivated pork muscle and 30% plant ingredients. The result is not a plant-based imitation; it is pork tissue grown in a different place.

Inside the Cultivated Bacon Prototype

The technical claim behind Higher Steaks’ bacon is straightforward: by weight, the bacon prototypes contain about 70% muscle cells grown in a bioreactor and 30% plant-based proteins and fats, with no bovine serum used in the process. Bovine fetal serum—an animal-derived growth medium—is one of the most criticized inputs in early cultured meat, both for ethical and scalability reasons. Replacing it with serum-free media is non-trivial; doing so at prototype stage signals that the company is working on ingredients that are more acceptable to consumers and regulators.

Hybridisation is doing two jobs here. First, it solves texture, binding, and mouthfeel challenges: plant fats and proteins can be tuned to deliver crispiness and structure where cell-grown tissue is still fragile. Second, it keeps cost and complexity within reach by reducing the amount of cultivated biomass required per strip. This is why the pork belly prototype sits at about 50% cultivated cells, while the bacon leans higher at 70%—belly demands larger, complex slabs of tissue, whereas thin rashers can rely more heavily on plant binders without sacrificing the experience.

This approach also clarifies an important point for safety debates. What is being evaluated is not a pure, single-substance meat; it is a composite food. Any eventual safety dossier would need to cover both the cell-derived fraction and the plant ingredients, just as regulators today assess composite products like sausages or ready meals.

Safety, Regulation, and the “Novel Food” Pathway

Higher Steaks presented its bacon as a prototype, not a commercial product. Company representatives were explicit: “There’s still a lot of work until it’s commercial,” and retail availability was described as several years away. That is not mere caution; in the UK, any cell-cultivated food must be authorised before sale and is treated as a novel food under the Food Standards Agency (FSA) framework. This authorisation involves submission of detailed data on toxicology, allergenicity, microbiological safety, composition, and manufacturing controls, followed by independent expert assessment.

In the record we have, no such product-specific dossier for Higher Steaks’ bacon is publicly available. There is no regulatory finding declaring it unsafe, but there is also no formal approval that would allow it onto supermarket shelves. The prototype sits in a pre-market space: promising, technically sophisticated, yet still awaiting the kind of evidence package regulators require before sign-off. This is typical of cultivated meat globally. Scientific and regulatory reviews recognise plausible safety advantages—controlled environments, no farm antibiotics, fewer opportunities for zoonotic contamination—but also emphasise that there is “a lack of transparency and scarcity of publicly available scientific data” about industrial-scale cultivated meat safety, and call for systematic residue, contamination, and process-hazard testing.

The broader regulatory pattern reinforces this. In Singapore, the first jurisdiction to approve cultivated meat, authorities granted pre-market approval only after detailed safety reviews and continue to sample and test products. So far, they report no detected food safety concerns in the authorised cultured meat sold there. In the United States, the FDA has completed pre-market consultations for cultivated chicken, concluding those products are safe to eat and handing off oversight of slaughter and labelling to the USDA. Higher Steaks’ bacon is not yet in that league; it is an R&D milestone awaiting the same level of scrutiny.

Why Cultivated Bacon Matters for Environment and Animal Welfare

To understand why a single prototype strip matters, you have to look at pork’s footprint. Pork is the most widely consumed meat globally, accounting for more than a third of total meat intake, and bacon is one of its most culturally entrenched forms. Conventional pig farming is land- and water-intensive, relies heavily on feed crops, and contributes to greenhouse gas emissions, manure pollution, and antibiotic resistance. Cultivated meat advocates argue that growing meat from cells can drastically reduce these impacts: one cited Oxford modelling exercise estimates that lab-grown meat could cut greenhouse gas emissions by up to 96%, land use by 98%, and energy use roughly by half relative to traditional livestock, under favourable assumptions.

The Higher Steaks team leans directly into these arguments. They describe their process as slaughter-free, antibiotic-free, and far more carbon-friendly and hygienic than animal agriculture. By removing the need to raise and kill pigs, cultivated bacon could eliminate animal welfare concerns linked to intensive pig farming—such as confinement, tail docking, and transport stress—while also lowering the risk of foodborne illness stemming from slaughterhouse contamination. A controlled bioreactor environment is easier to monitor and sanitize than open barns or abattoirs, which is why regulators and some industry experts expect cultivated meat to carry lower microbial contamination risks than conventional meat, provided manufacturing is well run.

What Comes Next for Bacon Without Pigs

Looking ahead, the key tasks for turning prototypes into everyday food are less glamorous than the first lab-grown strip but far more decisive. First is regulatory evidence: companies will need to submit detailed dossiers covering not just pathogens but also residual growth media components, structural materials, and potential novel allergens associated with cell culture. Independent laboratories, not just company scientists, will likely need to validate these claims. Second is manufacturing scale. Hybrid products like Higher Steaks’ bacon are an intentional bridge—by leaning on plant ingredients they lower the burden on cell cultivation systems—but they still require reliable, contamination-controlled bioreactors and cost-effective media.

Third, and perhaps most politically complex, is public understanding. Cultivated bacon is easily caricatured as “Frankenfood,” especially when coverage uses shorthand like “lab meat.” Yet the underlying technique—growing tissues from cells—is well established in biomedical science and has been used safely for decades in other contexts. The challenge is explaining to consumers what they are actually eating, how it differs from conventional bacon, and why the safety controls are at least as robust as those applied to current meat processing.

If those hurdles are met, bacon without pigs could shift from curiosity to category. For consumers who value the flavour and cooking qualities of pork but are uneasy about industrial farming, a cruelty-free strip grown from a vial of cells may prove deeply attractive. For regulators, the priority will be ensuring that this attraction is backed by hard data on safety and consistent manufacturing practices. For farmers, the story is more uncertain: cultivated bacon may eventually erode demand for some conventional pig products, but it might also coexist as a niche premium option or even create new markets for specialty breeds supplying cell lines.